Compare Page
Tesamorelin vs Sermorelin
Quick verdict: Tesamorelin vs sermorelin is a comparison between two GHRH-pathway compounds with very different clinical standing. Tesamorelin is the only FDA-approved GHRH analogue (Egrifta SV), with RCT-grade visceral fat reduction data. Sermorelin is a truncated GHRH fragment (first 29 amino acids) that lost its FDA approval in 2008 due to manufacturing issues, not safety concerns.[1][2][3] Both stimulate pituitary GH release through the same receptor, but evidence depth is not comparable. A common follow-up question — sermorelin vs tesamorelin vs ipamorelin — adds a ghrelin-pathway compound to the comparison; ipamorelin works through a different receptor entirely (see below).
Read the full peptide profiles: Tesamorelin and Sermorelin.
At a Glance: Tesamorelin vs Sermorelin
Who Each One Usually Fits Better
Tesamorelin usually fits better for people who prioritise evidence depth and want the strongest clinical backing available for a GHRH-pathway compound. The FDA approval, multiple RCTs, and CT-measured visceral fat reduction data are unmatched by any other secretagogue. If the primary goal is body-composition trending with hard evidence, tesamorelin has the stronger case.[1] Searches for tesamorelin vs sermorelin for bodybuilding or muscle growth reflect this — tesamorelin’s CT-measured visceral fat data is the closest thing to body-recomposition evidence in the GHRH-pathway compound class.
Sermorelin usually fits better for people in recovery and anti-aging contexts who want GHRH-pathway GH support with a well-understood safety profile. The compound has decades of clinical use history, even though the evidence base is thinner than tesamorelin’s. Many sermorelin vs tesamorelin searches come from cost-comparison contexts — sermorelin is typically more accessible.[2][3] Queries like tesamorelin vs sermorelin for weight loss and for women are common; both compounds act through the same GH-axis pathway regardless of sex, but neither has dedicated weight-loss RCT data comparable to GLP-1 agonists.
Effects Comparison (Practical)
Visceral fat context: tesamorelin has dedicated RCT data showing CT-measured trunk fat reduction. Sermorelin does not have equivalent body-composition trial data. This is the clearest differentiator — tesamorelin’s fat-reduction signal is evidence-backed, sermorelin’s is inferred from GH-axis activation.[1] For tesamorelin vs sermorelin for fat loss specifically, the evidence asymmetry is significant.
GH-axis activation: both stimulate pituitary GH release through the GHRH receptor. Tesamorelin’s longer amino acid sequence and stability modification may produce a more robust GH pulse, but direct head-to-head comparison data is limited.
Recovery and sleep context: sermorelin appears more frequently in recovery and sleep-quality discussions, though this framing is largely anecdotal rather than RCT-supported. Tesamorelin’s clinical focus has been body composition, not recovery endpoints.
Safety and Trade-Offs
- Both share GH-axis side effects — a frequent search as tesamorelin vs sermorelin side effects: injection site reactions, arthralgia, fluid retention, and potential glucose effects.
- Tesamorelin has a formal prescribing label with documented adverse event rates from Phase III trials — a data advantage over sermorelin.
- Sermorelin’s FDA withdrawal was due to manufacturing issues (EMD Serono discontinued production), not safety signals. The compound’s safety profile from decades of clinical use is generally well-characterised.
- Both produce short-duration GH pulses rather than sustained elevation — mechanistically cleaner than exogenous GH but requiring daily administration.
- Effect reversal on discontinuation is documented for tesamorelin and expected for sermorelin based on the shared mechanism.
Who It’s Not For (Quick Filter)
- People expecting tesamorelin-level evidence from sermorelin — the data quality gap is real.
- People expecting either compound to replace training fundamentals for body composition.
- People seeking dosing protocols — this page is informational context only.
FAQ
Tesamorelin vs sermorelin: which has better evidence?
Tesamorelin, by a significant margin. It has FDA approval, multiple RCTs with CT-measured outcomes, and a formal prescribing label. Sermorelin’s evidence base is older, thinner, and its FDA approval was withdrawn in 2008.
Is sermorelin cheaper than tesamorelin?
Generally yes. Sermorelin is more widely available through compounding pharmacies at lower cost. Tesamorelin (Egrifta SV) is a branded pharmaceutical product with higher pricing. Many comparison searches are driven by this cost differential.
Can this page provide tesamorelin or sermorelin dosage guidance?
No. This page is informational only and does not provide dosing protocols. It focuses on comparison context, evidence quality, and practical trade-offs.
Why was sermorelin’s FDA approval withdrawn?
EMD Serono voluntarily discontinued manufacture in 2008, leading to FDA approval withdrawal. This was a business and manufacturing decision, not a safety withdrawal. The compound’s safety profile from clinical use was not the reason for discontinuation.
Tesamorelin vs sermorelin vs ipamorelin: how do all three compare?
Different pathways. Tesamorelin and sermorelin are GHRH-pathway compounds (stimulate GH via GHRH receptor). Ipamorelin is a ghrelin-mimetic (stimulates GH via GHS receptor). Tesamorelin has the strongest evidence. For the ipamorelin comparison, see the dedicated profiles.
Do tesamorelin and sermorelin have the same side effects?
Both share GH-axis class effects: injection site reactions, joint discomfort, fluid retention, and potential glucose impact. Tesamorelin has more detailed adverse event data from Phase III trials. Individual variability applies to both.
Is tesamorelin better than sermorelin?
In terms of clinical evidence, yes. Tesamorelin has FDA approval, multiple RCTs, and CT-measured body-composition data. Sermorelin’s evidence base is older and thinner. Whether “better” applies to a specific context depends on goals, budget, and evidence tolerance — sermorelin is more accessible and has decades of clinical safety history.
Sermorelin vs tesamorelin vs ipamorelin: how do all three compare?
Tesamorelin and sermorelin are GHRH-pathway compounds — they stimulate GH release through the GHRH receptor. Ipamorelin is a ghrelin-mimetic that works through a completely different receptor (GHS-R). Tesamorelin has the strongest evidence. Sermorelin is the most accessible. Ipamorelin is the most commonly paired with other secretagogues. For the full ipamorelin comparison, see the ipamorelin vs tesamorelin page.
Tesamorelin vs sermorelin vs CJC-1295: which GHRH compound has the best evidence?
Tesamorelin, by a significant margin. It is the only FDA-approved GHRH analogue with multiple phase III RCTs. Sermorelin has older GH-deficiency studies but lost FDA approval in 2008. CJC-1295 has one published pharmacokinetic study and no body-composition trials. For the direct CJC-1295 comparison, see tesamorelin vs CJC-1295.
References
- [1] Falutz J, et al. Effects of tesamorelin on visceral fat reduction in HIV-infected patients. J Clin Endocrinol Metab. 2010;95(9):4291-4304. PMID: 20581389.
- [2] Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. PMID: 18046908.
- [3] Merriam GR, et al. Growth hormone-releasing hormone in normal aging: an update. Horm Res. 2003;60(Suppl 1):134-140. PMID: 12566733.